fr
Article scientifique
Anglais

Intra-monocyte Pharmacokinetics of Imiglucerase Supports a Possible Personalized Management of Gaucher Disease Type 1

Publié dansClinical Pharmacokinetics, vol. 58, no. 4, p. 469-482
Date de publication2019
Résumé

Intravenous imiglucerase enzyme replacement therapy for Gaucher disease type 1 administered every 2 weeks is at variance with the imiglucerase plasma half-life of a few minutes. We hypothesized that studying the pharmacokinetics of imiglucerase in blood Gaucher disease type 1 monocytes would be more relevant for understanding enzyme replacement therapy responses.

Mots-clés
  • Adolescent
  • Adult
  • Aged
  • Aged, 80 and over
  • Child
  • Enzyme Replacement Therapy
  • Female
  • Gaucher Disease/drug therapy/metabolism
  • Glucosylceramidase/metabolism/pharmacokinetics/therapeutic use
  • Humans
  • Male
  • Middle Aged
  • Models, Biological
  • Monocytes/metabolism
  • Precision Medicine
  • Young Adult
Citation (format ISO)
BERGER, Juliette et al. Intra-monocyte Pharmacokinetics of Imiglucerase Supports a Possible Personalized Management of Gaucher Disease Type 1. In: Clinical Pharmacokinetics, 2019, vol. 58, n° 4, p. 469–482. doi: 10.1007/s40262-018-0708-8
Fichiers principaux (1)
Article (Published version)
accessLevelRestricted
Fichiers secondaires (1)
Identifiants
ISSN du journal0312-5963
161vues
0téléchargements

Informations techniques

Création15/10/2020 16:17:00
Première validation15/10/2020 16:17:00
Heure de mise à jour15/03/2023 23:44:24
Changement de statut15/03/2023 23:44:22
Dernière indexation17/01/2024 11:59:31
All rights reserved by Archive ouverte UNIGE and the University of GenevaunigeBlack